Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and Acceptance

Exclusion Criteria12

• Known or suspected hypersensitivity to study intervention(s) or related products.
• Previous randomisation in this study.
• Previous rescreening for this study.
• Pregnant or breastfeeding female participants.
• Current participation (i.e., signed informed consent) in any other interventional clinical study. Treatment with an investigational medical product within 3 months or 5 half-lives (if known), whichever is longer prior to screening.
• Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol, including insufficient abdominal area for injection.
• Intake of any medication that could influence pain perception or injection site reaction appearance (e.g., anti-coagulants, including low dose of aspirin, systemic antihistamines, pain-relieving, or anti-inflammatory medicinal products) within the last week before the intervention.
• Intake of alcohol within the last 24 hours (self-reported) or a positive result of alcohol breath test prior to randomisation and intervention.
• Intake of illicit drugs within the last 48 hours (self-reported) or a positive result of urine drug screening prior to screening.
• Use of any nicotine products within the past month before screening.
• Known active or inactive skin condition or disease, tattoos, or other interventions in the injection area that may affect pain perception or assessment of injection-site reactions.
• Strenuous exercise within 3 days prior to the intervention.